ArticleFrontiers in toxicology2026
Case Report: High-dose pregabalin ingestion in an adolescent: clinical course and serial plasma concentrations.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pregabalin (PGB) is widely used for neuropathic pain, generalized anxiety disorder, and seizure management; however, recent epidemiological data highlight a progressive increase in its misuse and involvement in intoxications, particularly among adolescents and individuals with psychiatric comorbidities. Although dose-toxicity relationships have been explored in adult populations, substantial interindividual variability persists, and data in pediatric or adolescent patients remain limited. Establishing clearer associations between ingested dose, serum concentrations, and clinical severity is essential to guide management strategies and identify cases requiring advanced interventions such as extracorporeal removal. Case Presentation: We describe the case of a 16-year-old girl who intentionally ingested 2,700 mg (54 mg/kg, based on the patient's body weight of 51 kg) of immediate-release pregabalin. She presented at the Emergency Care Unit 10 h after ingestion with marked somnolence, psychomotor slowing, and bilateral horizontal nystagmus, while vital signs, renal and hepatic function tests remained normal. Electrocardiography revealed only mild PR interval prolongation. Serial plasma concentrations of Pregabalin demonstrated a decline from 16.5 mg/L at 12 h to 8.4 mg/L at 18 h and 0.69 mg/L at 34 h, consistent with expected pharmacokinetics. No gastrointestinal decontamination was performed due to delayed presentation, and no extracorporeal treatments were deemed necessary. Patient was subjected to a clinical conservative management, and progressively recovered without neurological sequelae. Conclusion: Despite ingestion of a dose commonly associated with moderate to severe toxicity, the patient exhibited a mild and self-limited clinical course, emphasizing the variability of pregabalin toxicity in adolescents. Clinical assessment remains the primary guide, while serum concentrations provide supportive information when available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.